Search - tctmd.com

Displaying 321 - 340 of 474

Sort: Relevancy | Date

News Featured Fellow

J. Raider Estrada, MD

Yael L. Maxwell

January 31, 2016

News Opinion Editor's Corner

The Gift of Data: Medical Journals Back Public Data Disclosure as Prerequisite for Publishing

Shelley Wood

January 24, 2016

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

News Featured Fellow

Benjamin Z. Galper, MD, MPH

Yael L. Maxwell

November 15, 2015

News Conference News AHA 2015

Continuous Chest Compressions During CPR Do Not Enhance Cardiac Arrest Outcomes

Caitlin E. Cox

November 09, 2015

News Conference News AHA 2015

Female Cardiologists Underpaid and Outnumbered, with Ramifications for Patients and Profession

Shelley Wood

November 09, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

Shelley Wood to Join CRF as Editorial Director

October 14, 2015

News Conference News TCT 2015

Linnemeier Young Investigator Award Goes to Toby Rogers, BM BCh

October 13, 2015

News Industry News

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

October 12, 2015

News Industry News

Scripps experts present at 2015 TCT scientific symposium

October 09, 2015

News Industry News

Tamir Wolf, MD, PhD Joins the Cardiovascular Research Foundation as Senior Director, Operations and Development for the CRF Clinical Trials Center

October 08, 2015

News Daily News

Interventional Cardiology ABIM Certification Not Strongly Linked to PCI Outcomes

Todd Neale

October 01, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Features

When Paths Diverge—and Converge: Manish and Sahil Parikh Make Their Mark as Brothers, Clinicians, and Educators

Nicole Lou

August 15, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Featured Fellow

Kimberly Atianzar, MD

Yael L. Maxwell

July 20, 2015

News Opinion Fellow Talk

5 Tips for Successfully Matching With an Interventional Cardiology Fellowship Program

Sarah Elsayed, MD

July 13, 2015

Advertisement

J. Raider Estrada, MD

The Gift of Data: Medical Journals Back Public Data Disclosure as Prerequisite for Publishing

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Benjamin Z. Galper, MD, MPH

Continuous Chest Compressions During CPR Do Not Enhance Cardiac Arrest Outcomes

Female Cardiologists Underpaid and Outnumbered, with Ramifications for Patients and Profession

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Shelley Wood to Join CRF as Editorial Director

Linnemeier Young Investigator Award Goes to Toby Rogers, BM BCh

Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease

Scripps experts present at 2015 TCT scientific symposium

Tamir Wolf, MD, PhD Joins the Cardiovascular Research Foundation as Senior Director, Operations and Development for the CRF Clinical Trials Center

Interventional Cardiology ABIM Certification Not Strongly Linked to PCI Outcomes

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

When Paths Diverge—and Converge: Manish and Sahil Parikh Make Their Mark as Brothers, Clinicians, and Educators

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Kimberly Atianzar, MD

5 Tips for Successfully Matching With an Interventional Cardiology Fellowship Program

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content